SPOTLIGHT -
FDA Approves Pfizer COVID-19 Vaccine for Those Ages 16 Years and Older
The full approval for BNT162b2 (Comirnaty; Pfizer/BioNTech) will afford physicians greater prescribing capability and is expected to play a role in driving workplace vaccine mandates.
Johnson & Johnson COVID-19 Vaccine Paused After Reports of Cerebral Venous Thrombosis
The FDA and CDC made the call after 6 reports of the serious blood clot event, which has so far been linked to 1 patient death.
Moderna COVID-19 Vaccine Shows Promise, Moves to Phase 3
The findings support the advancement of a 100-mcg dose vaccine to a phase 3 trial assessment in later summer 2020, while a phase 2 trial of a pair of different doses continues among 600 healthy adults.
Quarterly Infusions of Eptinezumab Highly Effective for Migraine Prevention in PROMISE 2
The intravenous quarterly CGRP inhibitor eptinezumab significantly reduced monthly migraine days compared with placebo for patients with chronic migraine.
Eptinezumab Migraine Prevention Sustained in 12-Month Analysis
More than two-thirds of patients treated with intravenous infusions of the CGRP inhibitor eptinezumab had an average 50% reduction in migraines.
